Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-Blind, Adjuvant- and Placebo-Controlled, Dose-Escalating Study to Evaluate Safety, Tolerability, and Immunogenicity of Leish-111f + MPL-SE Vaccine With Meglumine Antimoniate (Glucantime) in Cutaneous Leishmaniasis

NCT00111553 is registered in ClinicalTrials.gov with Access to Advanced Health Institute (AAHI) as lead sponsor.

NCT NCT00111553
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00111553 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-Blind, Adjuvant- and Placebo-Controlled, Dose-Escalating Study to Evaluate Safety, Tolerability, and Immunogenicity of Leish-111f + MPL-SE Vaccine With Meglumine Antimoniate (Glucantime) in Cutaneous Leishmaniasis
Lead sponsor
Access to Advanced Health Institute (AAHI)
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2004
Completion date
August 31, 2006
Enrollment
45
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

leishmaniasis, cutaneous